Dr Popat on OS Outcomes With Amivantamab Plus Chemotherapy in EGFR-Mutated, Advanced NSCLC

Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research, discusses findings from the second interim overall survival (OS) analysis of the phase 3 MARIPOSA-2 study (NCT04988295) investigating amivantamab-vmjw (Rybrevant) plus chemotherapy in patients with 

-mutated, advanced non–small cell lung cancer who have progressed on osimertinib (Tagrisso).

Videos

Sanjay Popat, BSc, MBBS, FRCP, PhD, discusses OS data with amivantamab plus chemotherapy in EGFR-mutated, advanced NSCLC after progression on osimertinib.

Sanjay Popat, BSc, MBBS, FRCP, PhD

Articles

Dr Popat on OS Outcomes With Amivantamab Plus Chemotherapy in EGFR-Mutated, Advanced NSCLC